Experiences with interferon-beta-1b treatment in MS after three year follow-up

Experiences with interferon-beta-1b treatment in MS after three year follow-up

Bibliographic Details
Main Authors:	T Járdánházy, M Török
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2002-05-01
Series:	Swiss Medical Weekly
Subjects:	Multiple sclerosis Interferonbeta1b
Online Access:	https://www.smw.ch/index.php/smw/article/view/164

Similar Items

Phylogenetic and In Silico Analysis of Interferon Beta-1b Protein
by: Ziaeddin Mirhoseini, et al.
Published: (2017-02-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
by: Masoud Mohammad Malekzadeh, et al.
Published: (2020-06-01)

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
by: Mark S. Freedman, et al.
Published: (2024-01-01)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
by: Dian HE, et al.
Published: (2014-09-01)

Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient with Multiple Sclerosis Treated with Interferon-Beta
by: Pegah Sadat Fatehi, et al.
Published: (2018-11-01)

Interferon-beta injection site reactions in patients with multiple sclerosis
by: Martina Maurelli, et al.
Published: (2018-11-01)

Safety of Use of Russian Biosimilars of Interferon Beta-1b in the Treatment of Multiple Sclerosis: a Meta-analysis of Original Studies
by: D. O. Gudz, et al.
Published: (2019-06-01)

Diplopia Associated with Interferon-b1a Treatment: Report of a Case
by: Özge Saraç
Published: (2011-09-01)

Diplopia Associated with Interferon-b1a Treatment: Report of a Case
by: Özge Saraç
Published: (2011-09-01)

Interferon Beta-1a versus Combined Interferon Beta-1a and Oligodendrocyte-Specific FGFR1 Deletion in Experimental Autoimmune Encephalomyelitis
by: Ranjithkumar Rajendran, et al.
Published: (2022-10-01)

The Effect of Beta Interferon on the Expression of miR-145 in Patients with Multiple Sclerosis
by: Naeim Ehtesham, et al.
Published: (2016-11-01)

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
by: Miraç Ayşen Ünsal
Published: (2019-03-01)

Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review
by: Carmen Adella Sirbu, et al.
Published: (2020-04-01)

Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study
by: Raed Al-Roughani, et al.
Published: (2023-11-01)

MS and exercise (PP-23)
by: Maryam Abolhasani, et al.
Published: (2023-01-01)

Paroxysmal Events in Multiple Sclerosis (MS); Pseudoathetosis as a Presenting Symptom of MS (ORP-48)
by: Ahmad Chitsaz
Published: (2023-01-01)

Interferon Beta: Analysis of Information on Adverse Reactions and Evaluation of Possibility of Signal Identification
by: K. E. Zatolochina, et al.
Published: (2019-06-01)

Comorbidity in patients with MS (ORP-19)
by: Fereshteh Ashtari
Published: (2023-01-01)

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
by: Carla Rodriguez-Mogeda, et al.
Published: (2023-09-01)

Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study
by: Laura Rosa, et al.
Published: (2022-09-01)

<i>ADAR</i> Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy
by: Fakhr Fakhr, et al.
Published: (2023-09-01)

Fuzzy Logic System for Classifying Multiple Sclerosis Patients as High, Medium, or Low Responders to Interferon-Beta
by: Edgar Rafael Ponce de Leon-Sanchez, et al.
Published: (2023-08-01)

OPPORTUNITIES OF ANTI B-CELL THERAPY IN MULTIPLE SCLEROSIS
by: E. P. Evdoshenko, et al.
Published: (2014-07-01)

Interferon Lambda Signaling Restrains Experimental Autoimmune Encephalomyelitis
by: Mohammad Asif Sherwani, et al.
Published: (2024-02-01)

Early cognitive dysfunction as a marker for the poor course of multiple sclerosis: a prospective 12-year follow-up
by: D. S. Kasatkin, et al.
Published: (2019-11-01)

Care ethics and empathic Practices in dealing with MS Patients (ORP-62)
by: Hanieh Zaer Rezaei
Published: (2023-01-01)

Epidemiological view of national MS registry in Iran (NMSRI) (ORP-27)
by: Sharareh Eskandarieh
Published: (2023-01-01)

Everything we need to know about vaccination in MS (ORP-12)
by: Hossein Mozhdehipanah
Published: (2023-01-01)

Antigen B modulates anti‐inflammatory cytokines in the EAE model of multiple sclerosis
by: Aliakbar Mariki, et al.
Published: (2023-02-01)

Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS)
by: N Razazian, et al.
Published: (2020-04-01)

Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis
by: O. V. Boyko, et al.
Published: (2019-03-01)

Flow Cytometry Analysis of Peripheral Blood B Cell Distribution of Patients with Multiple Sclerosis
by: Vuslat Yılmaz, et al.
Published: (2017-12-01)

MS Variants (ORP-38)
by: Ebrahim Kouchaki
Published: (2023-01-01)

Demographic Patterns of MS Patients Using BRISA: An MS-Specific App in Germany
by: Preetha Balakrishnan, et al.
Published: (2022-07-01)

Neurosarcoidosis in an adult man with a family history of MS: A Case report (PP-26)
by: Elham Sadat Azimi
Published: (2023-01-01)

Vitamin B1 Intake in Multiple Sclerosis Patients and its Impact on Depression Presence: A Pilot Study
by: Jose Enrique de la Rubia Ortí, et al.
Published: (2020-08-01)

Risk factors increasing the incidence of multiple sclerosis (MS)
by: Monika Kuc, et al.
Published: (2022-08-01)

Dual Role of B Cells in Multiple Sclerosis
by: Gaurav Kumar, et al.
Published: (2023-01-01)

role of an occupational therapist in working with people with MS in the opinion of patients
by: Paulina Aleksander-Szymanowicz, et al.
Published: (2022-07-01)

Multiple sclerosis : recovery of function and neurorehabilitation /
by: Kesselring, Jurg, et al.
Published: (c201)